Medtronic Raises 2027 Forecast Amid Heart Device Demand Surge

Medtronic has raised its fiscal 2027 revenue growth and profit forecasts, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant now anticipates an annual organic revenue growth between 7.25% and 7.75%, up from its previous projection of 6.75% to 7.25%. The company also increased the lower end of its adjusted per share profit forecast to $5.94 from $5.90, maintaining the upper limit at $6.

Strategic Investments and Market Expansion

In a strategic move to expand its market reach, Medtronic announced an $80 million investment in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the United States. CEO Geoff Martha highlighted the complementary nature of Cornerstone's Sentire device with Medtronic's Hugo system, noting the significant potential in emerging markets where soft tissue robotic surgery penetration remains below 1%.

Strong Performance Across Segments

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which experienced an 88% surge. The portfolio is utilized in treating irregular heart rhythms and has been a key contributor to the company's recent performance.

The company's financial results for the quarter exceeded expectations, with an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion. This surpassed the estimates compiled by LSEG, which anticipated a profit of $1.39 per share on $9.55 billion in sales.

Tariff Refunds and Future Outlook

Medtronic's Finance Chief Thierry Pieton noted that tariff refunds received during the quarter nearly offset the duties paid, though future refunds have not been factored into the company's outlook. CEO Geoff Martha expressed confidence in Medtronic's growth trajectory, emphasizing the company's focus on high-growth segments with large patient pools. "We've had a steady cadence of M&A," Martha stated, underscoring Medtronic's commitment to strategic investments in promising areas of medical technology.